Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Breast Cancer Breast Cancer—Local/Regional/Adjuvant

Breast Cancer—Local/Regional/Adjuvant

Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery.
 
Martin Sjöström, S. Laura Chang, Linda Hartman, et al.
 
 
A novel biosignature identifies DCIS patients with a poor biologic subtype with an unacceptably high rate of local recurrence after breast conserving surgery and radiotherapy.
 
Frank Vicini, Chirag Shah, Pat W. Whitworth, et al.
 
 
Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF <50%).
 
Pamela N. Munster, Roy Tamura, Jeffrey Krischer, et al.
Clinical trial information: NCT01009918
 
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.
 
Evandro de Azambuja, Daniel Eiger, Marion Jennifer Procter, et al.
Clinical trial information: NCT01358877
 
Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
 
Frederic Amant, Valentina Nekljudova, Charlotte Maggen, et al.
 
 
Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.
 
Matteo Lambertini, Luca Boni, Andrea Michelotti, et al.
Clinical trial information: NCT00311636
 
Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).
 
Miguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
Clinical trial information: NCT03155997
 
Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.
Frederik Marmé, Miguel Martin, Michael Untch, et al.
Clinical trial information: NCT01864746
 
Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.
 
Carsten Denkert, Frederik Marmé, Miguel Martin, et al.
 
 
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial.
 
Joseph A. Sparano, Anne M. O'Neill, Noah Graham, et al.
Clinical trial information: NCT00433511
 
Usefulness of assessment of circulating tumor DNA(ctDNA) of cerebrospinal fluid(CSF) samples for early detection of brain metastasis (BrM) in patients with triple-negative breast cancer (TNBC).
 
Lucrezia Raimondi, Giuseppe Naso, Rachele Lazzeroni, et al.